FABIANA AGENA
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
7 resultados
Resultados de Busca
Agora exibindo 1 - 7 de 7
conferenceObject A Critical Analysis of Equations for MPA Exposure in Patients Under EC-MPS and Tacrolimus(2017) DAVID-NETO, E.; TRIBONI, A.; RAMOS, F.; AGENA, F.; ROMANO, P.; FREITAS, G.conferenceObject No Impact of One Year of Everolimus, as Compared to MPA, in the Reversal of Left Ventricular Hypertrophy in Elderly Renal Transplant Recipients - Preliminary Data from Then Everold Study(2017) DAVID-NETO, E.; AGENA, F.; FURTADO, M.; RODRIGES, A.; ANDRADE, J.; LEMOS, F.; PAULA, F.- Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients(2017) DAVID-NETO, Elias; AGENA, Fabiana; RAMOS, Fernanda; TRIBONI, Ana Heloisa Kamada; ROMANO, Paschoalina; EBNER, Persio de Almeida Rezende; COELHO, Venceslau; GALANTE, Nelson Zocoler; LEMOS, Francine Brambate CarvalhinhoBackground Although the proportion of elderly patients among renal transplant recipients has increased, pharmacokinetic (PK) studies of immunosuppressants rarely include older patients. Methods We studied 12-hour everolimus (EVL) PK in 16 elderly renal transplant recipients (all whites; 10 men; mean age, 64 2 years (61-71 years), in 4 separate timepoints (at 7, 30, 60, and 150 days) after EVL introduction, corresponding to a mean postrenal transplantation day: PK1 (43 4 days), PK2 (65 +/- 7 days), PK3 (106 +/- 17 days), and PK4 (206 +/- 40 days). Patients received EVL (target trough level (C-trough, 3-8 ng/mL), prednisone, and tacrolimus (TCL) (target C-trough, 2-5 ng/mL). Results Mean TCL-C-trough was 7.2 +/- 3.8, 4.9 +/- 2.2, 4.9 +/- 2.2, and 4.5 +/- 1.2 ng/mL at PK1, PK2, PK3, and PK4, respectively. There were no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 +/- 1.3 mg/d), C-trough (4.7 +/- 2.5 ng/mL), AUC(0-12h) (106 +/- 51 ng/h per mL), C-average (8.8 +/- 4.2 ng/mL), C-max (19.2 +/- 9.7 ng/mL), apparent Half-life (11.7 +/- 4.2 hours), estimated total body clearance (0.39 +/- 0.27 L/h), or fluctuation (166 +/- 65%). Also, none of those PK parameters differed statistically when adjusted for body weight. EVL-C-trough showed a very high correlation (r(2) = 0.849) with AUC(0-12h). Conclusions Our data indicate that elderly renal transplant recipients starting EVL 1 month after transplantation along with a steady-state TCL level, present stable EVL-PK parameters without significant changes in dose or exposure during the first 6 months after renal transplantation.
conferenceObject IMPACT OF EVEROLIMUS ADDED TO TACROLIMUS/MYCOPHENOLATE/ PREDNISONE ON CMV DISEASE AND ACUTE REJECTION IN SENSITIZED KIDNEY TRANSPLANT RECIPIENTS. A SINGLE CENTER, RANDOMIZED AND CONTROLLED, PILOT STUDY(2017) SOUZA, Patricia; VENTURA, Carlucci; AGENA, Fabiana; BARRETO, Noemia; REUSING, Jose Otto; ONUSIC, Vivian; ZOCOLER, Nelson; PAULA, Flavio De; DAVID-NETO, EliasconferenceObject Defining a BKV Cutt-Off and Profile for Early Detection of BKV Associated Nephropathy(2017) NIHEI, C.; AGENA, F.; PAULA, F.; DAVID, D.; FINK, M.; PIERROTTI, L.; DAVID-NETO, E.- Longitudinal Pharmacokinetics of Tacrolimus in Elderly Compared With Younger Recipients in the First 6 Months After Renal Transplantation(2017) DAVID-NETO, Elias; ROMANO, Paschoalina; TRIBONI, Ana Heloisa Kamada; RAMOS, Fernanda; AGENA, Fabiana; EBNER, Persio Almeida Rezende; ALTONA, Marcelo; GALANTE, Nelson Zocoler; LEMOS, Francine Brambate CarvalhinhoBackground. Elderly (Eld) (>= 60 years) recipients are receiving renal transplants more frequently. The pharmacokinetics (PK) studies of immunosuppressive drugs in healthy volunteers, rarely, include old patients. Methods. We studied 208 12-hour tacrolimus (TAC) PK (0, 20, 40, 60, 90, 120, 180, 240, 360, 480, 600, 720 min) in 44 Eld (65 +/- 3 years) and compared the results with 31 younger controls (Ctrl) (35 +/- 6 years) recipients, taking oral TAC/mycophenolate sodium (MPS)/prednisone, at 4 different timepoints: PK1 (8 +/- 2 days; n = 72), PK2 (31 +/- 4 days; n = 61), PK3 (63 +/- 6 days; n = 44), and PK4 (185 +/- 10 days; n = 31). Tacrolimus PK was measured by ultraperformance liquid chromatography coupled to a mass spectrometer repetition and noncompartmental PKs were analyzed using Phoenix WinNonlin. Results. Mean TAC dose was lower in the Eld group than in Ctrl ones throughout timepoints either by total daily dose or adjusted (Adj) per body weight. Mean TAC trough level (Cmin), used to adjust daily dose, was not different between the 2 groups in all timepoints. AdjCmax and AdjTAC-area under the curve at dosing interval were both higher in the Eld compared to the Ctrl group in PKs1, 3, and 4. Estimated total body clearance normalized by dose and weight was lower in the Eld group compared with the Ctrl in all PKs and statistically lower at PKs 1 and 3. Similar to younger recipients TAC trough level has also a high correlation (R-2 = 0.76) with area under the curve at dosing interval. Conclusions. These data indicate that Eld recipients have a lower TAC clearance and therefore need a lower TAC dose than younger recipients.
conferenceObject Senescence and Uremia Effects in Circulating T Cells Diverge in TREG Population and Cause T Cell Shift to a Memory Profile.(2017) FREITAS, G.; FERNANDES, M.; AGENA, F.; JABUUL, O.; COELHO, V.; LEMOS, F.; RAMOS, F.; TRIBONI, A.; DAVID-NETO, E.; GALANTE, N.